StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals UTB rollforward by Year

UTB rollforward — Additions for current year tax positions ($M) ($M)

Vertex Pharmaceuticals UTB rollforward: $120M in FY2025, up 0.3% from a year earlier.

Latest, FY2025
120
Period ended Dec 31, 2025
Change on a year earlier
+0.3%
119 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-K Note (Income Taxes — UTB Rollforward).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUTB rollforward — Additions for current year tax positions ($M) ($M)Year on yearSource
FY2025Dec 31, 2025120+0.3%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 2024119+2.8%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 2023116-9.6%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 2022128+205.5%Form 10-K (filed 2025-02-13) ↗
FY2021Dec 31, 202142+57.3%Form 10-K (filed 2024-02-15) ↗
FY2020Dec 31, 202026.7+84.1%Form 10-K (filed 2023-02-10) ↗
FY2019Dec 31, 201914.5+49.5%Form 10-K (filed 2022-02-09) ↗
FY2018Dec 31, 20189.70+155.3%Form 10-K (filed 2021-02-11) ↗
FY2017Dec 31, 20173.80–Form 10-K (filed 2020-02-13) ↗
FY2016Dec 31, 20160–Form 10-K (filed 2019-02-13) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals UTB rollforward ($M), annual FY2016–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/utb-inc-cur

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.